BioXcel Therapeutics has released its Q3 2025 financial results, reporting a decrease in net revenue from IGALMI® but also significantly reduced cost of goods sold. The company increased R&amp;D expenses due to heightened clinical trial activity while decreasing SG&amp;A expenses. BioXcel Therapeutics is advancing its late-stage clinical programs, including the SERENITY At-Home Phase 3 Safety Trial and the TRANQUILITY In-Care Phase 3 Trial, and plans to submit a supplemental New Drug Application (sNDA) in early Q1 2026 for the at-home use of IGALMI®.

BTAI

<p>BioXcel Therapeutics 发布了其 2025 年第三季度财务业绩，报告显示 IGALMI® 的净收入有所下降，但销售成本显著降低。由于临床试验活动增加，公司增加了研发费用，同时减少了销售及管理费用。BioXcel Therapeutics 正在推进其晚期临床项目，包括 SERENITY 在家阶段 3 安全试验和 TRANQUILITY 在护理阶段 3 试验，并计划在 2026 年第一季度初提交 IGALMI® 在家使用的补充新药申请（sNDA）</p>

Bioxcel Therapeutics 2025 年第三季度财务业绩及临床项目更新